Company
Gentian Diagnostics AS
Headquarters: Moss, Norway
Employees: 47
Market Cap
kr863.7 Million
NOK as of July 1, 2024
US$81.0 Million
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. It offers in-vitro diagnostic (IVD) for medical laboratories and universities. The company's products include the gentian calprotectin immunoassay used for the measurement of calprotectin in plasma and serum in the diagnosis of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; and Canine CRP, an IVD test for the quantitative determination of Canine CRP in dog serum plasma. It also develops NT-proBNP Immunoassay, a turbidimetric in vitro diagnostic test for the quantitative measurement of N-terminal pro-brain natriuretic peptide. The company was founded in 2001 and is headquartered in Moss, Norway.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Gentian Diagnostics AS has the following listings and related stock indices.
Stock: OSE: GENT wb_incandescent
Stock: FSX: 6FK wb_incandescent